[212Pb]VMT-alpha-NET

Phase 1

[212Pb]VMT-alpha-NET is one of 24 therapeutic programs targeting Somatostatin Receptor Positive. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Somatostatin Receptor PositiveRecruiting

Neuroendocrine CarcinomaRecruiting

Somatostatin Receptor PositivePreclinical

Recruiting

Neuroendocrine CarcinomaPhase 1

Recruiting

Competition

Competitive Landscape

25 competitors in Neuroendocrine Carcinoma

#DrugCompanyPhaseTrials

Eloxatin

Lenvima

Kyprolis

VVirionyx Corporation Limited

Sandostatin

Tarlatamab-Dznl

2 6

Tecentriq

Roche

Phase 2

2 7

Imfinzi

AstraZeneca

Phase 2

2 8

Opdivo

Bristol-Myers Squibb

Phase 2

2 9

Yervoy

Bristol-Myers Squibb

Phase 2

1 10

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Phase 1Recruiting

Neuroendocrine Carcinoma

NCT06479811

Q3 2039

PreclinicalRecruiting

Somatostatin Receptor Positive

NCT06427798

Clinical

Trials by Indication[1]

Neuroendocrine Carcinoma1 trial

Phase I Trial of [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT06479811·120 enrolled

Somatostatin Receptor Positive1 trial

Phase I/II Trial of Systemic Targeted Radioligand Therapy (TRT) With Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR Positive (SSTR+) Gastrointestinal (GI) Neuroendocrine Tumors (NET) and Pheochromocytoma/Paragangliomas Previously Treated With Systemic Radioligand Therapy

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT06427798·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for [212Pb]VMT-alpha-NET. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for [212Pb]VMT-alpha-NET. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: NNational Cancer Institute (NCI)

[212Pb]VMT-alpha-NET

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2032

Q3 2039

Trials by Indication[1]

Neuroendocrine Carcinoma1 trial

Somatostatin Receptor Positive1 trial

References

Drug Info

Quick Facts

Related News